All In Biotech

Drug Trial Radar · NCT04665154

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

A First-in-human, Randomized, Subject-blinded, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Jun 7, 2019

Primary completion

Aug 3, 2022

Study completion Aug 3, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is conducted to investigate the safety, tolerability and pharmacokinetics of MAS825 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • MAS825Drug

    single dose i.v. and s.c.

  • PlaceboDrug

    single dose i.v. and s.c.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse EventsTime frame: up to day 253

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Tempe, Arizona

  • Novartis Investigative Site

    Overland Park, Kansas

  • Novartis Investigative Site

    Mere Way, Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.